method for inhibiting immune evasion, method for treating immune dysfunction, method for enhancing an immune response, method for increasing expression of a major histocompatibility complex, method for increasing inflammation, method for treating cancer or cell proliferative disorder, method to determine the likelihood of efficacy of a treatment, and method for screening the efficacy of a treatment
it is a method for treating or alleviating a symptom of the disorder, for example, immune evasion, cancer cell-induced immune dysfunction, reduced immune response, decreased inflammation, decreased expression of a major histocompatibility complex (mhc), or cancer, distinguished by the aberrant, unregulated or increased zeste 2 homologue (ezh2) activity in a cell or individual in need thereof in contact with the cell or administering to the individual a therapeutically effective amount of an ezh2 inhibitor.trata-se de um método para tratar ou aliviar um sintoma de distúrbio, por exemplo, evasão imune, disfunção imune induzida por célula cancerígena, resposta imune reduzida, inflamação diminuída, expressão diminuída de um complexo de histocompatibilidade principal (mhc), ou câncer, distinguido pelo intensificador aberrante, desregulado ou aumentado de atividade de homólogo zeste 2 (ezh2) em uma célula ou indivíduo em necessidade do mesmo em contato com a célula ou administrar ao indivíduo uma quantidade terapeuticamente eficaz de um inibidor de ezh2.
